Immutep (IMMP) has released an update.
Immutep Limited reports promising preliminary results from the Phase IIb TACTI-003 trial, showing a 26.9% response rate for its novel immunotherapy drug eftilagimod alpha (efti) in tandem with KEYTRUDA in treating patients with PD-L1 negative first-line metastatic head and neck squamous cell carcinoma. This combination treatment could potentially offer a new therapeutic option for patients with limited treatment choices, particularly those unable to receive chemotherapy. The company anticipates releasing additional data, including complete response rates, in the first half of 2024.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
